Sandip Patel

77 An NGS assay to identify HLA loss of heterozygosity for future CEA and MSLN logic-gated CAR-T solid tumor protocols designed for reduced on-target, off-tumor toxicity

D. Maloney, M. Borad, S. Kopetz, 2022, Regular and Young Investigator Award Abstracts.

639 BASECAMP-1: Leveraging HLA loss of heterozygosity in solid tumors by NGS to identify patients with relapsed solid tumors for future CEA and MSLN logic-gated Tmod™ CAR T-cell therapy

Matthew J. Frigault, D. Miklos, D. Maloney, 2022, Regular and Young Investigator Award Abstracts.

263 A2B694, an autologous logic-gated cell therapy targeting mesothelin

M. Borad, S. Kopetz, J. Welch, 2022, Regular and Young Investigator Award Abstracts.

229 A2B530, an autologous CEA-directed Tmod T-cell therapy with an inhibitory receptor gated by HLA-A*02 to target colorectal, pancreatic, and lung cancer

D. Maloney, M. Borad, T. Welling, 2022, Regular and Young Investigator Award Abstracts.

772 A phase 1/2 dose escalation/expansion study evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of E-602, a bi-sialidase fusion protein, in advanced cancer (GLIMMER-01)

M. Sznol, I. Puzanov, A. El-Khoueiry, 2022, Regular and Young Investigator Award Abstracts.